Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. The Company has developed a proprietary product engine that employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat the known root cause of genetically defined diseases. It is using its product engine to identify targets that can be drugged by small molecules regardless of the particular underlying mechanism of gene mis-expression. The Company also identified drug targets to treat the root causes of facioscapulohumeral muscular dystrophy, or FSHD, and certain hemoglobinopathies, namely sickle cell disease, or SCD, and b-thalassemia. The Company has initiated a Phase IIb clinical trial of losmapimod, its product candidate for FSHD.